TrialHaematologica2018

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.

Anne-Sophie Michallet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.